Selected research
Industry Research
Biosimilars Drug Industry Research Report 2026
Market perspective
The global Biosimilars Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Biosimilars Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Biosimilars Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Biosimilars Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Biosimilars Drug include Sanofi, Qilu Pharmaceutical, Novartis, Eli Lilly, Pfizer, Zhejiang Hisun, Wockhardt, United Laboratory and Tonghua Dongbao, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Biosimilars Drug market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Biosimilars Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biosimilars Drug Market by Company
Sanofi
Qilu Pharmaceutical
Novartis
Eli Lilly
Pfizer
Zhejiang Hisun
Wockhardt
United Laboratory
Tonghua Dongbao
Shanghai Henlius
Luye Pharma
Jiangsu Hengrui
Innovent Biologics
Geropharm
Gan&Lee
Dr Reddy’s
Celltrion
Celgen Biopharma
Bio-Thera
Biocon
3SBIO
Biosimilars Drug Segment by Type
Monoclonal Antibodies
Insulin
Others
Biosimilars Drug Segment by Application
Hospital
Retail Pharmacy
Other
Biosimilars Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilars Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biosimilars Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monoclonal Antibodies
- Insulin
- Others
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Sanofi
- Qilu Pharmaceutical
- Novartis
- Eli Lilly
- Pfizer
- Zhejiang Hisun
- Wockhardt
- United Laboratory
- Tonghua Dongbao
- Shanghai Henlius
- Luye Pharma
- Jiangsu Hengrui
- Innovent Biologics
- Geropharm
- Gan&Lee
- Dr Reddy’s
- Celltrion
- Celgen Biopharma
- Bio-Thera
- Biocon
- 3SBIO
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Biosimilars Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Monoclonal Antibodies
- 2.2.3 Insulin
- 2.2.4 Others
- 2.3 Biosimilars Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Biosimilars Drug Breakdown Data by Type
- 3.1 Global Biosimilars Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Biosimilars Drug Forecasted Market Size by Type (2027-2032)
4 Biosimilars Drug Breakdown Data by Application
- 4.1 Global Biosimilars Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Biosimilars Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Biosimilars Drug Market Perspective (2021-2032)
- 5.2 Global Biosimilars Drug Growth Trends by Region
- 5.2.1 Global Biosimilars Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Biosimilars Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Biosimilars Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Biosimilars Drug Market Dynamics
- 5.3.1 Biosimilars Drug Industry Trends
- 5.3.2 Biosimilars Drug Market Drivers
- 5.3.3 Biosimilars Drug Market Challenges
- 5.3.4 Biosimilars Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Biosimilars Drug Players by Revenue
- 6.1.1 Global Top Biosimilars Drug Players by Revenue (2021-2026)
- 6.1.2 Global Biosimilars Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Biosimilars Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Biosimilars Drug Head Office and Area Served
- 6.4 Global Biosimilars Drug Players, Product Type & Application
- 6.5 Global Biosimilars Drug Manufacturers Established Date
- 6.6 Global Biosimilars Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Biosimilars Drug Market Size (2021-2032)
- 7.2 North America Biosimilars Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Biosimilars Drug Market Size by Country (2021-2026)
- 7.4 North America Biosimilars Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Biosimilars Drug Market Size (2021-2032)
- 8.2 Europe Biosimilars Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Biosimilars Drug Market Size by Country (2021-2026)
- 8.4 Europe Biosimilars Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Biosimilars Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Biosimilars Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Biosimilars Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Biosimilars Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Biosimilars Drug Market Size (2021-2032)
- 10.2 South America Biosimilars Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Biosimilars Drug Market Size by Country (2021-2026)
- 10.4 South America Biosimilars Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Biosimilars Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Biosimilars Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Biosimilars Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Biosimilars Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi
- 12.1.1 Sanofi Company Information
- 12.1.2 Sanofi Business Overview
- 12.1.3 Sanofi Revenue in Biosimilars Drug Business (2021-2026)
- 12.1.4 Sanofi Biosimilars Drug Product Portfolio
- 12.1.5 Sanofi Recent Developments
- 12.2 Qilu Pharmaceutical
- 12.2.1 Qilu Pharmaceutical Company Information
- 12.2.2 Qilu Pharmaceutical Business Overview
- 12.2.3 Qilu Pharmaceutical Revenue in Biosimilars Drug Business (2021-2026)
- 12.2.4 Qilu Pharmaceutical Biosimilars Drug Product Portfolio
- 12.2.5 Qilu Pharmaceutical Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in Biosimilars Drug Business (2021-2026)
- 12.3.4 Novartis Biosimilars Drug Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Eli Lilly
- 12.4.1 Eli Lilly Company Information
- 12.4.2 Eli Lilly Business Overview
- 12.4.3 Eli Lilly Revenue in Biosimilars Drug Business (2021-2026)
- 12.4.4 Eli Lilly Biosimilars Drug Product Portfolio
- 12.4.5 Eli Lilly Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Biosimilars Drug Business (2021-2026)
- 12.5.4 Pfizer Biosimilars Drug Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 Zhejiang Hisun
- 12.6.1 Zhejiang Hisun Company Information
- 12.6.2 Zhejiang Hisun Business Overview
- 12.6.3 Zhejiang Hisun Revenue in Biosimilars Drug Business (2021-2026)
- 12.6.4 Zhejiang Hisun Biosimilars Drug Product Portfolio
- 12.6.5 Zhejiang Hisun Recent Developments
- 12.7 Wockhardt
- 12.7.1 Wockhardt Company Information
- 12.7.2 Wockhardt Business Overview
- 12.7.3 Wockhardt Revenue in Biosimilars Drug Business (2021-2026)
- 12.7.4 Wockhardt Biosimilars Drug Product Portfolio
- 12.7.5 Wockhardt Recent Developments
- 12.8 United Laboratory
- 12.8.1 United Laboratory Company Information
- 12.8.2 United Laboratory Business Overview
- 12.8.3 United Laboratory Revenue in Biosimilars Drug Business (2021-2026)
- 12.8.4 United Laboratory Biosimilars Drug Product Portfolio
- 12.8.5 United Laboratory Recent Developments
- 12.9 Tonghua Dongbao
- 12.9.1 Tonghua Dongbao Company Information
- 12.9.2 Tonghua Dongbao Business Overview
- 12.9.3 Tonghua Dongbao Revenue in Biosimilars Drug Business (2021-2026)
- 12.9.4 Tonghua Dongbao Biosimilars Drug Product Portfolio
- 12.9.5 Tonghua Dongbao Recent Developments
- 12.10 Shanghai Henlius
- 12.10.1 Shanghai Henlius Company Information
- 12.10.2 Shanghai Henlius Business Overview
- 12.10.3 Shanghai Henlius Revenue in Biosimilars Drug Business (2021-2026)
- 12.10.4 Shanghai Henlius Biosimilars Drug Product Portfolio
- 12.10.5 Shanghai Henlius Recent Developments
- 12.11 Luye Pharma
- 12.11.1 Luye Pharma Company Information
- 12.11.2 Luye Pharma Business Overview
- 12.11.3 Luye Pharma Revenue in Biosimilars Drug Business (2021-2026)
- 12.11.4 Luye Pharma Biosimilars Drug Product Portfolio
- 12.11.5 Luye Pharma Recent Developments
- 12.12 Jiangsu Hengrui
- 12.12.1 Jiangsu Hengrui Company Information
- 12.12.2 Jiangsu Hengrui Business Overview
- 12.12.3 Jiangsu Hengrui Revenue in Biosimilars Drug Business (2021-2026)
- 12.12.4 Jiangsu Hengrui Biosimilars Drug Product Portfolio
- 12.12.5 Jiangsu Hengrui Recent Developments
- 12.13 Innovent Biologics
- 12.13.1 Innovent Biologics Company Information
- 12.13.2 Innovent Biologics Business Overview
- 12.13.3 Innovent Biologics Revenue in Biosimilars Drug Business (2021-2026)
- 12.13.4 Innovent Biologics Biosimilars Drug Product Portfolio
- 12.13.5 Innovent Biologics Recent Developments
- 12.14 Geropharm
- 12.14.1 Geropharm Company Information
- 12.14.2 Geropharm Business Overview
- 12.14.3 Geropharm Revenue in Biosimilars Drug Business (2021-2026)
- 12.14.4 Geropharm Biosimilars Drug Product Portfolio
- 12.14.5 Geropharm Recent Developments
- 12.15 Gan&Lee
- 12.15.1 Gan&Lee Company Information
- 12.15.2 Gan&Lee Business Overview
- 12.15.3 Gan&Lee Revenue in Biosimilars Drug Business (2021-2026)
- 12.15.4 Gan&Lee Biosimilars Drug Product Portfolio
- 12.15.5 Gan&Lee Recent Developments
- 12.16 Dr Reddy’s
- 12.16.1 Dr Reddy’s Company Information
- 12.16.2 Dr Reddy’s Business Overview
- 12.16.3 Dr Reddy’s Revenue in Biosimilars Drug Business (2021-2026)
- 12.16.4 Dr Reddy’s Biosimilars Drug Product Portfolio
- 12.16.5 Dr Reddy’s Recent Developments
- 12.17 Celltrion
- 12.17.1 Celltrion Company Information
- 12.17.2 Celltrion Business Overview
- 12.17.3 Celltrion Revenue in Biosimilars Drug Business (2021-2026)
- 12.17.4 Celltrion Biosimilars Drug Product Portfolio
- 12.17.5 Celltrion Recent Developments
- 12.18 Celgen Biopharma
- 12.18.1 Celgen Biopharma Company Information
- 12.18.2 Celgen Biopharma Business Overview
- 12.18.3 Celgen Biopharma Revenue in Biosimilars Drug Business (2021-2026)
- 12.18.4 Celgen Biopharma Biosimilars Drug Product Portfolio
- 12.18.5 Celgen Biopharma Recent Developments
- 12.19 Bio-Thera
- 12.19.1 Bio-Thera Company Information
- 12.19.2 Bio-Thera Business Overview
- 12.19.3 Bio-Thera Revenue in Biosimilars Drug Business (2021-2026)
- 12.19.4 Bio-Thera Biosimilars Drug Product Portfolio
- 12.19.5 Bio-Thera Recent Developments
- 12.20 Biocon
- 12.20.1 Biocon Company Information
- 12.20.2 Biocon Business Overview
- 12.20.3 Biocon Revenue in Biosimilars Drug Business (2021-2026)
- 12.20.4 Biocon Biosimilars Drug Product Portfolio
- 12.20.5 Biocon Recent Developments
- 12.21 3SBIO
- 12.21.1 3SBIO Company Information
- 12.21.2 3SBIO Business Overview
- 12.21.3 3SBIO Revenue in Biosimilars Drug Business (2021-2026)
- 12.21.4 3SBIO Biosimilars Drug Product Portfolio
- 12.21.5 3SBIO Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst